In this work, we have demonstrated that fepA was also negatively controlled, but by a TetR-type repressor. TetR proteins constitute a well-known family of transcriptional repressors. They have been extensively studied in the regulation of several genes for drug efflux systems, such as TetR and tetA in E. coli, AcrR and acrAB in E. coli, AdeN and AdeIJK in Acinetobacter baumannii, or QacR and qacA/qacB in S. aureus. As previously reported for other TetR-like repressors, FepR also autoregulates expression of its own gene. As opposed to what was observed for fepR, TetR-likeencoding genes are usually divergently transcribed and are not part of an operon with the structural gene for the efflux pump. Finally, no data are available about the expression of efflux pumps during the cell cycle. For fepA, it seems to be highly expressed during the exponential phase, like most of the genes controlled by s70 factors, but further investigations are needed. In conclusion, this is the first characterization of a MATE efflux pump involved in FQ resistance in L. monocytogenes. The substrate profile appears to be narrow, including only hydrophilic FQs. Finally, we also report transcriptional regulation of the expression of a MATE family efflux pump-encoding gene through a TetR-like repressor. Similar molecular mechanisms may be involved in FQ resistance within other important gram-positive pathogens in which FepA homologs are chromosomally encoded and for which FQ are indicated. Liver ischemia reperfusion injury is a clinically relevant condition that occurs during resection surgery, Gentamycin Sulfate trauma, hypovolemic shock, or transplantation when liver is transiently deprived of oxygen and reoxygenated. These conditions result in hepatic dysfunction and failure as well as remote organ injury. The pathophysiology of liver IRI includes direct cellular damage as the result of the ischemic insult as well as delayed dysfunction and damages that result from activation of inflammatory pathways. Clinical and experimental data have established that up to 10% early graft dysfunction and higher incidence of both acute and chronic rejection are associated with IRI, and therefore, it dampens the long-term graft survival. Hepatic injuries caused by IRI are now recognized as a result of highly complex mechanisms, among which, the role of T lymphocytes has been proved of great importance and as a key mediator of IRI. These studies indicate that T lymphocyte is the key regulator in initiating and propagating the injury response. One may therefore speculate whether a reduction in T lymphocytes may reduce the incidence and severity of IR-induced complications. IL-2R-specific monoclonal antibody was used in clinics to inhibit most of the IL-2/IL-2R interaction for a considerable time, and prevented rejection in organ transplantation. It acts as an antagonist at the interleukin-2 binding site of the p55 subunit of the high affinity IL-2 receptor on the surface of the activated T lymphocytes and inhibits the binding of serum IL-2 to CD25, there by inhibiting the proliferation of activated T cells and subsequent release of cytokines. However, one of the most important conflicts is that the current interventions targeting the IL-2R through antiCD25 mAb can reduce the number and function of Treg cells, and eventually aggravate the IR injury. In the present study, we sought to elucidate whether Dimesna near-term intervention targeting the IL-2R through anti-CD25 mAb might compromise the number or function of Treg cells in the liver.